 | |
 | |
| Combination of | |
|---|---|
| Segesterone acetate | Progestogen |
| Ethinylestradiol | Estrogen |
| Clinical data | |
| Trade names | Annovera |
| Other names | EE/SGA; EE/SA |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a604032 |
| License data | |
| Routes of administration | Intravaginal |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Segesterone acetate/ethinylestradiol (EE/SGA), sold under the brand name Annovera, is a contraceptive vaginal ring and combined form of hormonal birth control which contains segesterone acetate, a progestin and ethinylestradiol, an estrogen.[1][2][3] It contains 17.4 mg ethinylestradiol and 103 mg segesterone acetate, releases an average of 13 μg ethinylestradiol and 0.15 mg segesterone acetate per day.[1][4]
Annovera is inserted into the vagina and left for 21 days, then removed, washed and stored for seven days, during which the user experiences a period (withdrawal bleeding.) This can be repeated thirteen times, for one full year of use.[5] Unlike NuvaRing, another vaginal ring contraceptive, Annovera does not need to be refrigerated before being dispensed and can be stored at temperatures up to 30 degrees Celsius.[1]
The medication was developed by the Population Council, an international non-profit organization, and licensed to TherapeuticsMD. It was approved for medical use in the United States in August 2018.[4][6]
See also
References
- ^ a b c d "Annovera- segesterone acetate and ethinyl estradiol ring". DailyMed. 7 August 2020. Retrieved 10 October 2020.
- ^ Nelson AL (October 2019). "Comprehensive overview of the recently FDA-approved contraceptive vaginal ring releasing segesterone acetate and ethinylestradiol: A new year-long, patient controlled, reversible birth control method". Expert Review of Clinical Pharmacology. 12 (10): 953–963. doi:10.1080/17512433.2019.1669448. PMID 31526281. S2CID 202674265.
- ^ Lee AL (May 2020). "Segesterone Acetate and Ethinyl Estradiol Vaginal Ring (Annovera) for Contraception". American Family Physician. 101 (10): 618–620. PMID 32412221.
- ^ a b "TherapeuticsMD Announces FDA Approval of Annovera (Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control". TherapeuticsMD Inc (Press release). 10 August 2018. Retrieved 10 October 2020.
- ^ "FDA approves new vaginal ring for one year of birth control". U.S. Food and Drug Administration (FDS) (Press release). 10 August 2018. Retrieved 10 October 2020.
- ^ "Drug Approval Package: Annovera (segesterone acetate and ethinyl estradiol)". U.S. Food and Drug Administration (FDA). 10 September 2018. Retrieved 10 October 2020.
External links
- "Segesterone acetate". Drug Information Portal. U.S. National Library of Medicine.
- "Ethinylestradiol". Drug Information Portal. U.S. National Library of Medicine.
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 8 August 2022, at 03:37